Hester Bios Q1 FY27 Results (NSE: HESTERBIO)
Signal: Margin expansion
The read
Standalone operations delivered a clean beat — revenue +14% YoY, gross margin expanding 900bps to 78%, EBITDA margin +15pp to 36%, PAT +88% — reflecting strong poultry vaccine demand and operating leverage from new facilities. Consolidated PAT is distorted by an exceptional ₹853.49 Mn gain; underlying consolidated EBITDA margin (pre-exceptional) was ~34%, also healthy. The Animal Healthcare division remains weak due to government order timing; this is a lumpy but not structural issue.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹77.24 Cr | -8% | -22.8% |
| EBIT | ₹111.81 Cr | 327% | |
| Net profit | ₹96.73 Cr | 459% | |
| EPS | ₹113.71 | 459.3% | |
| EBIT margin | 144.7% |
P&L walk
Consolidated revenue fell 8% YoY due to sharp drop in Animal Healthcare division, but gross margin expanded to 78% (+5pp) on better mix. EBITDA margin before exceptional stood at ~34%, reflecting operating improvement. PAT exploded to ₹967.32 Cr on a ₹853.49 Cr exceptional gain from Gates Foundation loan modification — without this, PAT would have been ~₹113.8 Cr, still above year-ago on standalone strength.
Segments
Poultry Healthcare drove the group's operating strength with revenue up 47.5% YoY to ₹621.33 Mn and segment result up 163% to ₹243.07 Mn; Animal Healthcare turned into a drag with revenue -64% YoY and a segment loss of ₹41.85 Mn vs profit of ₹132.11 Mn a year ago, due to delayed government programmes.
Key positives
- Standalone gross margin expanded 900bps YoY to 78%, the highest in at least 5 quarters, driven by favourable product mix and operational efficiencies.
- Poultry Healthcare division revenue surged 48% YoY (standalone) / 47.5% YoY (consolidated), reflecting strong institutional demand and deeper market penetration.
- Standalone EBITDA grew 95% YoY to ₹260.34 Mn, with EBITDA margin of 36% (+15pp), demonstrating significant operating leverage as employee costs grew only 0.5% YoY.
- Exceptional gain of ₹853.49 Mn from Gates Foundation loan modification significantly de-risks the Africa subsidiary's balance sheet: principal reduced from USD 12M to USD 5M, all accrued interest waived, and the revised loan is interest-free.
Key concerns
- Consolidated revenue fell 8% YoY due to a 64% drop in Animal Healthcare division, impacted by delayed government immunisation programmes — a recurring lumpiness risk.
- Animal Healthcare division swung from a profit of ₹132.11 Mn (Q1FY26) to a loss of ₹₹41.85 Mn (Q1FY27), dragging consolidated segment results.
- Standalone revenues declined 22.5% QoQ, partly seasonal (Q4 typically higher due to year-end government orders), but the magnitude is notable.
- Consolidated PAT of ₹967.32 Mn is largely non-recurring — excluding the exceptional gain, PAT would be ~₹113.8 Mn, still robust but 88% lower than headline.
Research and educational content only. Not investment advice.